Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effectsMethods for high-density admixture mapping of disease genesFunctionally defective germline variants of sialic acid acetylesterase in autoimmunityA high-density admixture map for disease gene discovery in african americansGenetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisEpstein-Barr virus infection is not a characteristic feature of multiple sclerosis brainThe role of the CD58 locus in multiple sclerosisMeta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility lociDysregulated T cell expression of TIM3 in multiple sclerosisRegulatory T cells in autoimmune neuroinflammationMultiple sclerosis-a quiet revolutionRole of "Western diet" in inflammatory autoimmune diseasesProspects of immune checkpoint modulators in the treatment of glioblastomaPromotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cellsDifferential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cellsLack of TIM-3 immunoregulation in multiple sclerosisAn RNA profile identifies two subsets of multiple sclerosis patients differing in disease activityGenetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell linesAn autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cellsLysosomal cysteine and aspartic proteases are heterogeneously expressed and act redundantly to initiate human invariant chain degradationGenetic and epigenetic fine mapping of causal autoimmune disease variantsFOXP3+ regulatory T cells in the human immune systemGenome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.Risk alleles for multiple sclerosis identified by a genomewide studyA model for harmonizing flow cytometry in clinical trials.Pervasive sharing of genetic effects in autoimmune disease.Polyfunctional responses by human T cells result from sequential release of cytokines.Models of somatic hypermutation targeting and substitution based on synonymous mutations from high-throughput immunoglobulin sequencing data.Characterization of in vivo expanded OspA-specific human T-cell clones.Joint modeling and registration of cell populations in cohorts of high-dimensional flow cytometric dataBiomarkers in multiple sclerosis.Class II MHC self-antigen presentation in human B and T lymphocytesUncoupling p70(s6) kinase activation and proliferation: rapamycin-resistant proliferation of human CD8(+) T lymphocytes.Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.A local antigen-driven humoral response is present in the inflammatory myopathies.IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production.Automated high-dimensional flow cytometric data analysis.RNA interference screen in primary human T cells reveals FLT3 as a modulator of IL-10 levels.A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01.Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene.
P50
Q21090198-39B1A4A7-145E-4DA6-BD3C-4A2A625CE579Q22337164-4711B50B-D0EE-4101-8B56-B4FEFFF30FCAQ24322817-B1D1767D-8FFA-4544-A89E-F154D7FB0653Q24533390-B18E0F6D-AF00-4DD5-940D-D881341058CFQ24635370-F2C3825B-DF29-4F2F-9291-09B582F9CD52Q24642187-FCAAF31B-70A2-44B0-9886-C4377E5431B2Q24649291-26CEC10E-C8EC-48B5-BFA1-B961F92B968BQ24656799-9DEFA13B-2F23-4E27-9C0C-7537A83FCA36Q24676780-20E64AAC-DFBA-4B3E-A36C-1275CD054D69Q26825063-6A438F88-B25A-42AF-82FB-D26DDE3F7410Q26826930-D58271BC-DF20-493F-B138-3232C322CD5EQ26996114-BC486F58-6E43-47F7-BB38-0EA55C45CA29Q28081371-E96D0191-CF2E-49F4-86A5-E09CE614EA05Q28117145-576DEDA8-F43A-4729-B7D7-0222EEA9D60DQ28261709-47106C42-7C64-4351-803D-83EF291B0D83Q28273324-B5BAF5BE-F819-4AB3-B7ED-F5F2BD6A1357Q28275948-DA3142B4-443F-448F-A7E2-E8467E3074D6Q28474104-595F8B2D-A80E-4BD7-8414-69F66D3203B8Q28610420-6340A265-BCA2-434D-AA64-6EDC33FF7B77Q28612372-C4A56C2C-0B0A-4519-A8BA-4ED2D24E6452Q28649603-FA14365F-9092-4A8F-9615-F77C5A272EDEQ29307487-A006E4B3-1C25-4B91-9295-D6821973A360Q29417047-09C6C46A-2DFF-465E-A813-E9CC334E2077Q29614890-F3BEE7EB-9AA3-46C4-A0A1-126B4263B467Q30425924-343CCE49-0A98-49A7-8CDD-A776B7845C1DQ30431030-1CEE3360-177A-492C-84E4-B21021FE1796Q30505101-E7033935-224D-4E7E-99EA-A93232868B2DQ30706182-90E5CCE5-BD6C-4249-BA7F-8BBA020A2E13Q30783677-BD65693E-D4B8-4177-8EAF-AA9BCE3A1C54Q30834407-CC296578-0EBC-47AE-B856-77FA5E3DDDF3Q30978587-FAC0736A-FB06-4213-87EE-C209BD4981FEQ31047483-3E045008-E15C-44DD-B6AB-1DBF9AF5ECCEQ32024520-38AE8D57-30A8-4AB1-959B-D26747738B08Q33180102-F0285C76-6B0D-409F-924A-4E3FF4326B11Q33267230-E2C6E936-88C2-4C98-BE92-D9C52AC2DCE1Q33396971-6BABCBC9-5C4C-4225-AF2F-51BC4962FB7AQ33445872-AEE8C217-0B81-4A6F-82A6-11E10B7D4C11Q33519448-04FE5A41-D9D5-43CA-BCC4-C95614630172Q33622435-39361483-C27E-4BE3-B776-392444219776Q33645905-2C30F22F-B30C-4CAA-96CE-B2230D1FE2A3
P50
description
American neurologist
@en
neurolojiste american
@lfn
neurowetenschapper
@nl
neurólogo estadounidense
@es
usona neŭrologo
@eo
name
David A. Hafler
@ast
David A. Hafler
@en
David A. Hafler
@es
David A. Hafler
@nl
type
label
David A. Hafler
@ast
David A. Hafler
@en
David A. Hafler
@es
David A. Hafler
@nl
prefLabel
David A. Hafler
@ast
David A. Hafler
@en
David A. Hafler
@es
David A. Hafler
@nl
P21
P2381
P31
P569
1952-01-01T00:00:00Z